Encouraging results from a study of real-world psilocybin services in Oregon

For years, some of the most compelling evidence for psilocybin has come from tightly controlled clinical trials at major research institutions. Those studies have helped establish the potential of psilocybin-assisted interventions for conditions ranging from depression and anxiety to substance use disorders.

But an important question remains: What happens when psilocybin moves out of the research laboratory and into the real world?

A new study from Oregon offers an intriguing early answer.

As reported in a recent NPR article, researchers followed people receiving legal psilocybin services through Oregon’s state-regulated program. Oregon became the first state in the country to establish a regulated system allowing adults to access psilocybin without participating in a clinical trial or obtaining a medical diagnosis or prescription.

The results are encouraging.

From Clinical Research to Real-World Practice

The prospective study followed 88 adults who received supervised psilocybin services between March 2024 and April 2025. Participants completed standardized measures of depression, anxiety, and well-being before their psilocybin session and again afterward.

This was a population with substantial mental health concerns. More than half reported a history of depression, 42% reported anxiety, and approximately 19% reported PTSD. Nearly half were taking psychiatric medications, and more than half were also participating in mental health therapy.

Thirty days after receiving psilocybin services, participants showed statistically significant improvements across all three primary outcomes.

The magnitude of the changes was particularly noteworthy. Depression scores decreased by an average of 4.63 points on the PHQ-8, while anxiety scores decreased by 4.85 points on the GAD-7. Both represented large effect sizes. Participants also reported substantial improvements in overall well-being.

Before their sessions, approximately 69% of participants reported at least mild depressive symptoms and 67% reported at least mild anxiety. One month later, 61% were reporting minimal depression and more than 70% were reporting minimal anxiety.

Why These Findings Matter

The significance of this research extends beyond the numbers.

Clinical trials are intentionally designed to control as many variables as possible. Participants are carefully screened, treatment protocols are standardized, and interventions often occur in academic medical settings with highly trained clinical teams.

Oregon represents something different.

Its model is explicitly not a medical treatment model. Adults 21 and older can access psilocybin at licensed service centers under the supervision of trained, licensed facilitators without a psychiatric diagnosis, physician referral, or prescription.

That makes Oregon an extraordinary real-world experiment in how psychedelic services might operate outside conventional healthcare.

Importantly, the early safety findings were also reassuring. Two participants reported short-term symptoms consistent with hallucinogen persisting perception disorder (HPPD) one day after their session. Those symptoms had resolved by the 30-day follow-up.

Encouraging, But Not Definitive

There are important reasons for caution.

This was a relatively small observational study, not a randomized controlled trial. There was no placebo or comparison group, participants knew they were receiving psilocybin, and nearly two-thirds had previous psychedelic experience. The findings therefore demonstrate an association between receiving psilocybin services and subsequent improvements. They cannot establish that psilocybin alone caused those improvements.

Access is another challenge. Cost was the most commonly reported barrier among study participants, highlighting an ongoing problem for state-regulated psychedelic programs: creating legal access does not necessarily create equitable access.

Still, these findings represent an important step.

The psychedelic field has spent decades asking whether psilocybin can produce meaningful change under carefully controlled research conditions. Oregon gives us an opportunity to begin asking the next question: Can those benefits translate into safe, effective services in the communities where people actually live?

The early evidence suggests that they may.

That should encourage continued research, not diminish the need for it. As Oregon’s program matures and Colorado's regulated natural medicine system develops, real-world data will become increasingly important in determining how we train facilitators, protect participants, improve access, and build psychedelic services that are both safe and effective.